|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Vir Biotechnology, Inc. (VIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
127,390,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. Co.'s existing pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus, influenza A virus, and human immunodeficiency virus. Co. has collaborate with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. to focus on treating and preventing severe acute respiratory syndrome coronavirus 2 (the virus that causes COVID-19 illness). Co. is developing differentiated monoclonal antibodies, like sotrovimab and VIR-7832, as well as vaccines and small molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
10,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$246,341 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
167,399 |
167,399 |
1,166,832 |
6,038,069 |
| Total Sell Value |
$1,671,921 |
$1,671,921 |
$27,667,686 |
$154,627,627 |
| Total People Sold |
5 |
5 |
9 |
11 |
| Total Sell Transactions |
10 |
10 |
30 |
125 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  De Backer Marianne |
Chief Executive Officer |
• • – |
2024-04-03 |
4 |
S |
$9.46 |
$690,365 |
D/D |
(72,995) |
678,457 |
|
- |
|
| Hanly Ann M. |
EVP & Chief Technology Officer |
• – – |
2024-04-01 |
4 |
S |
$10.05 |
$27,251 |
D/D |
(2,711) |
132,069 |
|
- |
|
| Lee Sung |
EVP & Chief Financial Officer |
• – – |
2024-03-27 |
4 |
S |
$9.89 |
$59,404 |
D/D |
(6,008) |
100,492 |
|
- |
|
| Scangos George A |
Director |
– • – |
2024-02-26 |
4 |
AS |
$11.65 |
$206,522 |
D/D |
(17,722) |
112,989 |
|
- |
|
| Scangos George A |
Director |
– • – |
2024-02-22 |
4 |
AS |
$10.05 |
$100,737 |
D/D |
(10,028) |
130,711 |
|
- |
|
| Pang Phillip |
EVP & Chief Medical Officer |
• – – |
2024-02-22 |
4 |
S |
$10.05 |
$146,344 |
D/D |
(14,568) |
250,111 |
|
- |
|
| De Backer Marianne |
Chief Executive Officer |
• • – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
751,452 |
|
- |
|
| Lee Sung |
EVP & Chief Financial Officer |
• – – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
106,500 |
|
- |
|
| Hanly Ann M. |
EVP & Chief Technology Officer |
• – – |
2024-02-22 |
4 |
S |
$10.05 |
$123,521 |
D/D |
(12,296) |
134,780 |
|
- |
|
| Hanly Ann M. |
EVP & Chief Technology Officer |
• – – |
2024-02-22 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
147,076 |
|
- |
|
| Scangos George A |
Director |
– • – |
2024-02-20 |
4 |
AS |
$10.22 |
$172,385 |
D/D |
(16,872) |
140,739 |
|
- |
|
| Scangos George A |
Director |
– • – |
2024-02-16 |
4 |
AS |
$10.24 |
$111,386 |
D/D |
(10,878) |
157,611 |
|
- |
|
| Pang Phillip |
EVP & Chief Medical Officer |
• – – |
2024-02-16 |
4 |
S |
$10.24 |
$34,006 |
D/D |
(3,321) |
264,679 |
|
- |
|
| Pang Phillip |
EVP & Chief Medical Officer |
• – – |
2024-01-02 |
4 |
OE |
$0.86 |
$110,299 |
D/D |
80,000 |
268,000 |
|
- |
|
| More Robert J |
Director |
– • – |
2023-10-19 |
4 |
A |
$0.00 |
$0 |
I/I |
6,405 |
495,890 |
|
- |
|
| More Robert J |
Director |
– • – |
2023-10-19 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,405) |
38,683 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-10-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,500,000 |
1,750,000 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-10-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,750,000) |
0 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-10-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,750,000) |
168,489 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-09-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,377,590) |
0 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,750,000 |
1,750,000 |
|
- |
|
| Scangos George A |
Director |
– • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750,000 |
1,918,489 |
|
- |
|
| Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
– – • |
2023-06-30 |
4 |
AS |
$25.11 |
$17,577 |
I/I |
(700) |
16,684,041 |
|
- |
|
| Sato Vicki L |
Director |
– • – |
2023-06-30 |
4 |
AS |
$24.66 |
$443,916 |
D/D |
(18,000) |
1,315,351 |
|
- |
|
| Softbank Vision Fund (aiv M1) L.p. |
10% Owner |
– – • |
2023-06-29 |
4 |
AS |
$25.18 |
$2,264,731 |
I/I |
(89,942) |
16,684,741 |
|
- |
|
575 Records found
|
|
Page 1 of 23 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
